Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 16/20 | 0.66 |
| ▸ | HTR1B | P28222 | 6/20 | 0.65 |
| ▸ | HTR1A | P08908 | 3/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | DRD1 | P21728 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.65 |
| ▸ | HTR1D | P28221 | 5/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR1F | P30939 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798333 | 1.00 | HTR6 (0.66) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| SCHEMBL505788 | 1.00 | HTR6 (0.66) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| SCHEMBL505789 | 1.00 | HTR6 (0.66) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| SCHEMBL10083480 | 1.00 | HTR6 (0.66) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| Bromide SCHEMBL505855 | 0.99 | HTR6 (0.65) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| Bromide SCHEMBL505856 | 0.99 | HTR6 (0.65) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| Bromide SCHEMBL505854 | 0.99 | HTR6 (0.65) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| SCHEMBL1069045 | 0.96 | HTR6 (0.64) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| SCHEMBL1069044 | 0.96 | HTR6 (0.64) | HTR6HTR1BHTR1ACHRM2ADRA2A | |
| SCHEMBL1069043 | 0.96 | HTR6 (0.64) | HTR6HTR1BHTR1ACHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090299077-A1 | Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan | PLUS CHEMICALS SA (CH) | 2009-12-03 | — | — | US | claimed |
| WO-2009142771-A2 | SALTS OF (R)-5-(2-PHENYLSULPHONYLETHENYL)-3-(N- METHYLPYRROLIDIN-2-YLMETHYL)-1H-INDOLE, 5-BROMO-3-[(R)-1- METHYL-PYRROLIDIN-2- YLMETHYL]-1H-INDOLE AND OF ELETRIPTAN | PLUS CHEMICALS, S.A. (CH) | 2009-11-26 | — | — | WO | claimed |
| EP-1660485-B1 | IMPROVED PROCESS FOR PREPARING ALPHA-POLYMORPHIC ELETRIPTAN HYDROBROMIDE | PFIZER LTD (GB) | 2006-12-27 | — | — | EP | claimed |
| US-20050245591-A1 | Process | PFIZER INC. | 2005-11-03 | — | — | US | claimed |
| US-20050020663-A1 | Process | FURLONG PATRICK JOSEPH (IE) | 2005-01-27 | — | — | US | claimed |
| US-8754239-B2 | Process for preparing eletriptan hydrobromide having α-form | SMS PHARMACEUTICALS LIMITED (IN) | 2014-06-17 | — | — | US | disclosed |
| US-20120027816-A1 | HIGHLY PURE ELETRIPTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF ELETRIPTAN N-OXIDE IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2012-02-02 | — | — | US | disclosed |
| WO-2012004811-A1 | PROCESS FOR THE PREPARATION OF 5-SUBSTSITUTED INDOLE DERIVATIVE | IND-SWIFT LABORATORIES LIMITED (IN) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011089614-A1 | PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM | SMS PHARMACEUTICALS LIMITED (IN) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011004391-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF ELETRIPTAN AND ITS SALT THEREOF | MATRIX LABORATORIES LTD (IN) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010097703-A1 | HIGHLY PURE ELETRIPTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF ELETRIPTAN N-OXIDE IMPURITY | ACTAVIS GROUP PTC EHF (IS) | 2010-09-02 | — | — | WO | disclosed |
| WO-2009142771-A3 | SALTS OF (R)-5-(2-PHENYLSULPHONYLETHENYL)-3-(N- METHYLPYRROLIDIN-2-YLMETHYL)-1H-INDOLE, 5-BROMO-3-[(R)-1- METHYL-PYRROLIDIN-2- YLMETHYL]-1H-INDOLE AND OF ELETRIPTAN | PLUS CHEMICALS, S.A. (CH) | 2010-01-14 | — | — | WO | disclosed |
| US-20050020663-A1 | Process | FURLONG PATRICK JOSEPH (IE) | 2005-01-27 | — | — | US | disclosed |
| US-20030166704-A1 | New process | PFIZER INC. | 2003-09-04 | — | — | US | disclosed |
| US-6201131-B1 | REACTING A 2-(ARYLSUFONYL) ETHANOL DERIVATIVE WITH AN ACID ANHYDRIDE IN PRESENCE OF A BASE, FURTHER REACTING THIS WITH AN AROMATIC HALIDE IN THE PRESENCE OF A PALLADIUM CATALYST; USEFUL AS INTERMEDIATES TO DRUGS, AGROCHEMICALS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-03-13 | — | — | US | disclosed |
| US-5607951-A | SEROTONIN AGONIST FOR NERVOUS SYSTEM DISORDERS, ANALGESICS AND PSYCHOTHERAPEUTICS | PFIZER INC (US) | 1997-03-04 | — | — | US | disclosed |
| US-5578612-A | Indole derivatives | PFIZER INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5559246-A | PROCESS OF DEHYDROHALOGENATION FOR CYCLIZATION TO PRODUCE PSYCHOTHERAPEUTIC AGENTS AND ANTISEROTONIN ANTAGONIST | PFIZER INC. (US) | 1996-09-24 | — | — | US | disclosed |
| US-5559129-A | SEROTONIN (5HT1) ANTAGONIST FOR TREATMENT OF DEPRESSION, ANXIETY, EATING DISORDERS, OBESITY, DRUG ABUSE, HEADACHES, AND PAIN | PFIZER INC (US) | 1996-09-24 | — | — | US | disclosed |
| US-5545644-A | SEROTONIN AGONISTS; HYPOTENSIVE AND ANXIOLYTIC AGENTS; ANALGESICS; ANTIDEPRESSANTS; EATING DISORDERS; DRUG ABUSE; HEADACHES; VASCULAR DISORDERS | PFIZER INC. (US) | 1996-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245591-A1 | Process | TPSD1, TPSAB1, TPSB2 | HTR6 260/4885HTR1B 81/4885HTR1A 29/4885 |
| US-20120027816-A1 | HIGHLY PURE ELETRIPTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF ELETRIPTAN N-OXIDE IMPURITY | SLC6A4, TPSD1, INMT | HTR6 92/4885HTR1B 274/4885HTR1A 42/4885 |
| US-20050020663-A1 | Process | TPSD1, TPSAB1, TPSB2 | HTR6 260/4885HTR1B 81/4885HTR1A 29/4885 |
| US-20030166704-A1 | New process | TFPI, HTR4, HTR5A | HTR6 20/4885HTR1B 32/4885HTR1A 19/4885 |
| US-20090299077-A1 | Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan | TPH1, SUCNR1, TPSD1 | HTR6 15/4885HTR1B 61/4885HTR1A 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.